January 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable electronic injector designed to enhance the administration of injectable medications while helping partners meet their sustainability goals.
Cambridge, MA. - January 7, 2025 – Portal Instruments, a leader in innovative drug delivery technology, recently announced the launch of PRIME Nexus, a cutting-edge reusable injector designed to enhance the administration of injectable medications. Built on Portal’s robust platform technology, the PRIME Nexus is a needle-based device designed to be compatible with standard primary containers, including 1mL pre-filled syringes (PFS), 2.25mL PFS, and 3mL cartridges.
The PRIME Nexus represents a significant advancement in drug delivery, offering precise control and versatility for a wide range of therapies. This innovative device is poised to be a game-changer for pharmaceutical companies and patients alike, offering several key advantages:
The PRIME Nexus is designed to seamlessly integrate into existing manufacturing and packaging processes, streamlining the development and commercialization of new injectable therapies. Its compatibility with standard primary containers further simplifies integration and reduces development timelines.
Portal Instruments will showcase the PRIME Nexus device at Pharmapack and other key industry events. Attendees will have the opportunity to see the device in action and discuss feasibility or development studies for this reusable injector.
About Portal Instruments:
Portal Instruments is a privately held medical device company focused on developing and commercializing innovative drug delivery platform technologies to transform the administration of injectable medications. Portal's goal is to improve patient experience, adherence, and outcomes by providing advanced delivery solutions.
June 7, 2023 Cambridge, MA – Portal Instruments is pleased to announce that Bill Rich has joined its Board of Directors. Mr. Rich is a seasoned executive with vast leadership experience in biotechnology, medical devices, and pharmaceuticals.
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
Please fill out the details below and we will get back to you shortly.